期刊文献+

SWI测量脑铁沉积在帕金森病中的临床应用价值 被引量:14

The application of measurement of the brain iron deposition in patients with Parkinson's disease on susceptibility weighted imaging
下载PDF
导出
摘要 目的拟通过磁敏感加权成像技术(SWI)评估帕金森病(PD)脑铁变化在校正相位图上造成的相位值的改变,探讨磁共振成像(MRI)对PD脑铁病理性改变的诊断价值。方法前瞻性收集原发性PD患者33例(PD组),另选健康自愿者22例为对照组(NC组)。所有PD患者采用Hoehn-Yahr分期,其中Hoehn-Yahr分期≤2.5期18例、>2.5期15例,行SWI序列扫描,在所得相位图上测量各脑区(双侧尾状核头、壳核、丘脑、黑质、红核、齿状核、苍白球)的相位位移值,利用公式f(x)=-x.π/4 096计算出各脑区的相位值。因相位值与脑铁沉积呈反比,分析相位值的差异可以半定量分析脑铁含量的分布。结果 PD组与NC组双侧尾状核头、苍白球、黑质相位值比较,差异有统计学意义(P<0.05),双侧壳核、丘脑、齿状核及红核相位值比较,差异无统计学意义。结论 SWI对显示脑内铁沉积非常敏感,可以通过测量相关脑区信号强度并计算出相位值以评价脑铁沉积,为活体研究PD脑铁含量提供了相对简单、无创的方法。 Objective To investigate the change of iron deposition in the brain of PD patients noninvasively by using SWI phase value and to provide a noninvasive and valuable biological indicator for the diagnosis of PD. Methods All patients were recruited from the in-patient and out-patient of the Anqing Petrol Hospital,which were diagnosed as primary Parkinson's disease during June 2010 and May 2012. There were 33 patients with PD(22 men, 11 women) aged 62. 1 ± 14. 2, who had a mean disease duration of 4.8 ± 3.7 years, and 22 age-matched volunteers ( 11 men and 11 women) as control group,the mean age were 62.2 ± 12. 4. There were no significant difference between the two groups in age. The SWI images were examined. The phase-shifted value of the bilateral head of caudate nucleus ( CAU), putamen ( PUT), thalamus ( TH ), substantia nigra ( SNr), red nucleus ( RN ), dentate mucleus ( DN ) and globus pallidus(GP) were evaluated in the corrected phase image. Phase values were obtained from the formula as follows: f(x) =-x . π/4 096. Statistical analysis was performed by using SPSS for Window( version 19.0). Resuits The phase value of bilateral CAU, SNr and PUT in PD group were significantly lower than that in the control group (P 〈 0.05 ). The phase value of bilateral RN, TH, DN and PUT had no significant difference between the two groups ( P 〉 0. 05 ). Conclusion SWI provides a non-invasive method for study of the process of pathological changes of iron deposition and diagnosis in PD.
出处 《安徽医科大学学报》 CAS 北大核心 2013年第5期523-526,共4页 Acta Universitatis Medicinalis Anhui
关键词 帕金森病 磁敏感加权成像 相位值 Parkinson' s disease susceptibility weighted imaging phase values
  • 相关文献

参考文献15

  • 1Atasoy H T, Nuyan 0,Tunc T, et al. T2-weighted MRI in Par-kinson ' s disease ; Substantia nigra parscompacta hypointensity cor-relateswith the clinical scores[ J]. Neurol India, 2004, 52(3):332 -7.
  • 2刘焯霖.帕金森病的诊断标准[J].中华神经外科杂志,2002,18(1):62-62. 被引量:34
  • 3Kennedy K M,Erickson K I,Rodrigue K M, et al. Age-relateddifferences in regional brain volumes: a comparison of optimizedvoxel-based morphometry to manual volumetry [ J ]. Neurobiol Ag-ing, 2009, 30(10):1657 -76.
  • 4王俊,姜宏,谢俊霞.中枢神经系统铁代谢与帕金森病的关系[J].生理科学进展,2003,34(1):67-70. 被引量:16
  • 5Salazar J,Mena N, Hunot S, et al. Divalent metal transporter 1(DMT1 ) contributes to neurodegeneration in animal models ofParkinson's disease [ J ]. Proc Natl Acad Sci U S A, 2008 , 105(47) :18578 -83.
  • 6Brar S,Henderson D,Schenck J, et al. Iron accumulation in thesubstantia nigra of patients with Alzheimer disease and Parkinson[J]. Arch Neurol,2009,66(3) : 371 -4.
  • 7Frost J J, Rosier A J, Reich S G, et al. Positron emission tomo-graphic imagine of the dopamine transporter with llC-win 35428reveals marked declines mild Parkinson's disease[ J]. Ann Neu-rol, 1993, 34:423 -31.
  • 8Wallis L I,Paley M N, Graham J M, et al. MRI assessment ofbasal ganglia iron deposition in Parkinson^ disease[ J] . Magn Re-son Imaging,2008,28(5) :1061 -7.
  • 9Berrshachar D,Youdim M B H. Intranigral iron injection inducesbehavioral and biochemical " Parkinsonism,' in rats [ J ]. Neuro-chem,1991,57:2133-5.
  • 10Graham J M,Paley M N,Grunewald R A, et al. Brain iron depo-sition in Parkinson ' s disease imaged using the PRIME magneticresonance sequence[ J]. Brain, 2000,123:2423 -31.

二级参考文献26

  • 1侯中煜,刘树伟.老化与帕金森病基底核的磁共振成像研究进展[J].解剖学报,2004,35(6):668-670. 被引量:3
  • 2Aarsland D, Andersen K, Larsen J P, et al. Risk of dementia in Parkinson' s disease : a community-based, prospective study [ J ]. Neurology, 2001, 56(6): 730-6.
  • 3Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson~ disease[ J]. Mov Disord, 2005, 20(10) : 1255 -63.
  • 4Wang Q s, Zhou J N. Retrieval and encoding of episodic memory in normal aging and patients with mild cognitive impairment [ J ]. Brain Res, 2002, 924( 1 ) :113 -5.
  • 5Sun Z W, Zhu Y X, Liu H Y, et al. Decreased cerebral blood flow velocity in apolipoprotein E epsilon4 allele carriers with mild cognitive impairment [ J ]. Eur J Neurol, 2007, 14 (2) : 150 - 5.
  • 6Hobson P, Meara J. The detection of dementia and cognitive impairment in a community population of elderly patients with Parkinson' s disease by use of the CAMCOG neuropsychological test[ J].Age Ageing, 1999,28( 1 ) :39 -43.
  • 7Athey R J, Porter R W, Walker R W. Cognitive assessment of a representative community population with Parkinson' s disease using the Cambridge Cognitive Assessment-Revised (CAMCOG-R) [J]. Age Ageing, 2005,34(3) :268 -73.
  • 8Athey R J, Walker R W. Demonstration of cognitive decline in Parkinson' s disease using the Cambridge Cognitive Assessment (Revised) (CAMCOG-R) [ J]. Int J Geriatr Psychiatry, 2006,21 (10) :977 - 82.
  • 9Gelb D J, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease[J]. Arch Neurol, 1999,56(1) :33 -9.
  • 10Roth M, Tyme E, Mountioy C Q, et al. CAMDEX. A standardized instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia[ J]. Br J Psychiatry, 1986,149:698 -709.

共引文献69

同被引文献132

  • 1赵望.磁敏感加权成像在帕金森病中的应用研究[J].医学信息(医学与计算机应用),2014,0(21):118-119. 被引量:1
  • 2Waragai M, Sekiyama K, Sekigawa A, et al. alpha-Synuclein and DJ 1 as potential biological fluid biomarkers for Parkinson's dis ease. Int J Mol Sci, 2010,11(11):4257-4266.
  • 3Jesse S, Steinacker P, Lehnert S, et al. Neuroehemical approa- ches in the laboratory diagnosis of Parkinson and Parkinson de- mentia syndromes: A review. CNS Neurosei Ther, 2009,15(2):157-182.
  • 4Salazar J, Mena N, Hunot S, et al. Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease. Proc Natl Acad Sci U S A, 2008, 105(47): 18578-18583.
  • 5Sofic E, Riederer P, Heinsen H, et al. Increased iron ( III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm, 1988,74(3) : 199-205.
  • 6Oakley AE, Collingwood JF, Dobson J, et al. Individual dopam- inergic neurons show raised iron levels in Parkinson disease. Neu- rology, 2007,68(21) : 1820-1825.
  • 7Zhang J, Zhang Y, Wang J, et al. Characterizing iron deposi- tion in Parkinson's disease using susceptibility weighted imaging: An in vivo MR study. Brain Res, 2010,1330:124-130.
  • 8Zhang W, Sun SG, Jiang YH, et al. Determination of brain iron content in patients with Parkinson's disease using magnetic sus- ceptibility imaging. Neurosci Bull, 2009,25(6):353-360.
  • 9Acosta-cabronero J, Williams GB, Cardenas-blanco A, et al. In vivo quantitative susceptibility mapping (QSM) in Alzheimer's disease. PLoS One, 2013,8(11):e81093.
  • 10Weinreb O, Mandel S, Youdim MB, et al. Targeting dysregula- tion of brain iron homeostasis in Parkinson's disease by iron che- lators. Free Radic Biol Med, 2013,62 : 52-64.

引证文献14

二级引证文献51

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部